Voyageur Pharmaceuticals Advances Barium Contrast Media Project with Frances Creek Initiative

Voyageur Pharmaceuticals ( (TSE:VM) ) has shared an update.

Voyageur Pharmaceuticals has initiated the Frances Creek barium contrast media project with the support of a $600,000 grant from Alberta Innovates. This project aims to produce natural, high-purity pharmaceutical grade barium sulfate as the primary ingredient in their contrast media products. The company is conducting clinical evaluations to compare the efficacy of their natural barium contrast media against existing synthetic options, potentially enhancing market positioning and driving sales growth. The ongoing Phase 1 clinical testing of their barium contrast media formulations is showing promising results, with a full product line expected to be cleared for market release in Canada following successful validation.

More about Voyageur Pharmaceuticals

Voyageur Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the development of barium contrast media products. The company is committed to creating a secure, vertically integrated supply chain for high-quality, cost-effective radiology products, addressing current market supply chain constraints.

YTD Price Performance: 35.90%

Average Trading Volume: 32,499

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $16.67M

See more insights into VM stock on TipRanks’ Stock Analysis page.